MOONLAKE IMMUNOTHERAPEUTICS: operating cash flow
Operating cash flow for MOONLAKE IMMUNOTHERAPEUTICS. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All MOONLAKE IMMUNOTHERAPEUTICS financial histories
What this measure means
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
Exact concept: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2021-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -196,007,000 | USD | 2026-02-25 | 10-K · 0001821586-26-000002 |
| 2024-01-01 | 2024-12-31 | -116,587,000 | USD | 2026-02-25 | 10-K · 0001821586-26-000002 |
| 2023-01-01 | 2023-12-31 | -42,778,000 | USD | 2026-02-25 | 10-K · 0001821586-26-000002 |
| 2022-01-01 | 2022-12-31 | -55,893,900 | USD | 2025-02-26 | 10-K · 0001821586-25-000006 |
| 2021-01-01 | 2021-12-31 | -611,071 | USD | 2022-02-17 | 10-K · 0001213900-22-008253 |
Related financial histories
- MOONLAKE IMMUNOTHERAPEUTICS: total assets
- MOONLAKE IMMUNOTHERAPEUTICS: total liabilities
- MOONLAKE IMMUNOTHERAPEUTICS: stockholders equity
- MOONLAKE IMMUNOTHERAPEUTICS: cash and cash equivalents
- MOONLAKE IMMUNOTHERAPEUTICS: net income or loss
- MOONLAKE IMMUNOTHERAPEUTICS: capital expenditure payments
- MOONLAKE IMMUNOTHERAPEUTICS: financing cash flow
- MOONLAKE IMMUNOTHERAPEUTICS: investing cash flow
- MOONLAKE IMMUNOTHERAPEUTICS: retained earnings or deficit
- MOONLAKE IMMUNOTHERAPEUTICS: basic weighted-average shares
- MOONLAKE IMMUNOTHERAPEUTICS: diluted weighted-average shares
- MOONLAKE IMMUNOTHERAPEUTICS: basic earnings per share
- MOONLAKE IMMUNOTHERAPEUTICS: diluted earnings per share
- MOONLAKE IMMUNOTHERAPEUTICS: income tax expense or benefit
- MOONLAKE IMMUNOTHERAPEUTICS: net property, plant and equipment
- MOONLAKE IMMUNOTHERAPEUTICS: share-based compensation expense
- MOONLAKE IMMUNOTHERAPEUTICS: operating income or loss
- MOONLAKE IMMUNOTHERAPEUTICS: current assets
- MOONLAKE IMMUNOTHERAPEUTICS: current liabilities
- MOONLAKE IMMUNOTHERAPEUTICS: common-stock repurchase payments
- MOONLAKE IMMUNOTHERAPEUTICS: operating expenses
- MOONLAKE IMMUNOTHERAPEUTICS: research and development expense
Inspect the source
- Entity
- MOONLAKE IMMUNOTHERAPEUTICS / CIK 0001821586
- Captured
- 2026-09-21T17:28:56.515Z
- SEC response SHA-256
5ec7814562ed5c855b3116fa30aee75dd24e176ae565286831b8e7bddfac283a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001821586.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))